Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943101 | 1.00 | SHBG (0.39) | SHBGESR1ARESR2LMNA | |
| SCHEMBL4945808 | 1.00 | SHBG (0.39) | SHBGESR1ARESR2LMNA | |
| SCHEMBL4944967 | 1.00 | SHBG (0.39) | SHBGESR1ARESR2LMNA | |
| SCHEMBL4942860 | 1.00 | SHBG (0.39) | SHBGESR1ARESR2LMNA | |
| SCHEMBL4939749 | 1.00 | SHBG (0.39) | SHBGESR1ARESR2LMNA | |
| SCHEMBL4941934 | 1.00 | SHBG (0.39) | SHBGESR1ARESR2LMNA | |
| SCHEMBL4939754 | 1.00 | SHBG (0.39) | SHBGESR1ARESR2LMNA | |
| SCHEMBL4945380 | 0.88 | ESR1 (0.40) | SHBGESR1ARESR2LMNA | |
| SCHEMBL4945781 | 0.88 | ESR1 (0.40) | SHBGESR1ARESR2LMNA | |
| SCHEMBL4938549 | 0.88 | ESR1 (0.40) | SHBGESR1ARESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130164780-A1 | Drug Identification Method | BIOVIE INC. | 2013-06-27 | — | — | US | disclosed |
| US-8354396-B2 | Identifying compounds that can treat autoimmune conditions; ulcerative colitis, inflammatory bowel disease, Crohn's disease, psoriasis, actinic keratosis, arthritis, multiple sclerosis, optic neuritis | Harbor Therapeutics, Inc. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8217025-B2 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | Harbor Therapeutics, Inc. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20080221074-A1 | Drug Screen and Treatment Method | BIOVIE INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080153792-A1 | Drug Identification and Treatment Method | BIOVIE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153797-A1 | Drug Identification and Treatment Method | BIOVIE INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080146532-A1 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | BIOVIE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153792-A1 | Drug Identification and Treatment Method | PTGER4, PTGER1, IL17A | SHBG 350/4885ESR1 93/4885AR 457/4885 |
| US-20080146532-A1 | Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance | HSD17B1, HSD17B11, HSD3B2 | SHBG 65/4885ESR1 96/4885AR 272/4885 |
| US-20080221074-A1 | Drug Screen and Treatment Method | HSD3B2, HSD17B2, HSD3B1 | SHBG 78/4885ESR1 59/4885AR 185/4885 |
| US-20080153797-A1 | Drug Identification and Treatment Method | PTGER4, PTGER1, IL17A | SHBG 343/4885ESR1 90/4885AR 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.